Brief: Cube Labs Unit Lipovexa Obtains U.S. Patent For New Therapeutic Platform For Treatment Of Metabolic Disorders
12/01/2026 06:22
Jan 12 (Reuters) - Cube Labs SpA CUBE.MI: UNIT LIPOVEXA OBTAINS U.S. PATENT FOR NEW THERAPEUTIC PLATFORM FOR TREATMENT OF METABOLIC DISORDERS Further company coverage: CUBE.MI (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Cube Labs SpA
See all newsBrief: Cube Labs Unit Gets European Patent Granted To Napa-Based Cream
Brief: Cube Labs H1 EBITDA €0.3 Mln
Brief: Cube Labs Says Insitutional Investor Completes Subscription Of 417,500 New Shares For EUR 1 Million
Brief: Cube Labs FY25 EBITDA At EUR 586,000
Brief: Cube Labs To Propose Capital Hike Up To EUR 15 Mln Within 5 Years